Table 6.
The results of SUCRA in the subgroup analysis on patients with severe baseline grade.
| Treatment | 4-Week healing rate | 8-Week healing rate | ||||
|---|---|---|---|---|---|---|
| SUCRA | PrBest | MeanBank | SUCRA | PrBest | MeanBank | |
| Kev20 | 57.1 | 11.9 | 4.4 | 89.6 | 71.0 | 1.9 |
| Vpz20 | 85.1 | 27.2 | 2.2 | 75.8 | 11.0 | 3.2 |
| Eso40 | 70.8 | 2.1 | 3.3 | 74.4 | 3.8 | 3.3 |
| Vpz40 | 84.1 | 55.3 | 2.3 | 55.0 | 8.6 | 5.0 |
| Pan40 | 47.9 | 3.2 | 5.2 | 48.8 | 0.7 | 5.6 |
| Rab20 | – | – | – | 44.4 | 4.1 | 6.0 |
| Lan30 | 41.2 | 0.0 | 5.7 | 41.8 | 0.0 | 6.2 |
| Ome20 | 33.8 | 0.0 | 6.3 | 40.1 | 0.0 | 6.4 |
| Lan60 | 30.1 | 0.3 | 6.6 | 30.0 | 0.7 | 7.3 |
| Placebo | 0.0 | 0.0 | 9.0 | 0.0 | 0.0 | 10.0 |
Eso40, Esomeprazole 40 mg qd; Fex40, Fexuprazan 40 mg qd; Ila10, Ilaprazole 10 mg qd; Kev20, Keverprazan 20 mg qd; Lan30, Lansoprazole 30 mg qd; Lan60, Lansoprazole 60 mg qd; Ome 40, Omeprazole 40 mg qd; Ome 20, Omeprazole 20 mg qd; Pan40, Pantoprazole 40 mg qd; Rab10, Rabeprazole 10 mg bid; Rab20, Rabeprazole 20 mg qd; SUCRA, surface under the cumulative ranking curve; Teg100, Tegoprazan 100 mg qd; Teg50, Tegoprazan 50 mg qd; Vpz20, Vonoprazan 20 mg qd; Vpz40, Vonoprazan 40 mg qd.